PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Wet Macular Degeneration

Drugs in development · updated 30 October 2026

Wet Macular Degeneration: drugs in development

As of 30 October 2026 there are 11 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for wet Macular Degeneration. 3 are experimental, that is not yet approved in the United States.

11Active trials
3Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
TiespectusII–III2NCT07440225
ADVM-022II1NCT05536973
RGX-314II1NCT03999801

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
AfliberceptEYLEA Injection, Ziv-AfliberceptII–III6NCT07440225
Bevacizumabavastin, MVASIIII1NCT05112861
RanibizumabLucentis, Ranluspec®II–III1NCT04704921
DoxycyclineDoxycyclin, Lymepak®II1NCT04504123

Sorted by most advanced phase and number of active trials.

All 7 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D057135 “Wet Macular Degeneration”.

ItalianoFrançaisDeutsch